Clene, Inc. (CLNN)
4.08
+0.06
(+1.49%)
USD |
NASDAQ |
Oct 02, 16:00
4.04
-0.04
(-0.98%)
After-Hours: 20:00
Clene EPS Diluted (Quarterly) : -1.084 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -1.084 |
| March 31, 2026 | -0.6949 |
| December 31, 2025 | -0.8801 |
| September 30, 2025 | -0.8534 |
| June 30, 2025 | -0.779 |
| March 31, 2025 | -0.0851 |
| December 31, 2024 | -1.675 |
| September 30, 2024 | -0.0609 |
| June 30, 2024 | -0.0528 |
| March 31, 2024 | -0.0863 |
| December 31, 2023 | -0.0792 |
| September 30, 2023 | -0.0188 |
| June 30, 2023 | -0.2922 |
| March 31, 2023 | -0.1548 |
| December 31, 2022 | -0.0141 |
| September 30, 2022 | -0.1728 |
| June 30, 2022 | -0.0716 |
| March 31, 2022 | -0.2125 |
| December 31, 2021 | 0.071 |
| Date | Value |
|---|---|
| September 30, 2021 | 0.4133 |
| June 30, 2021 | -0.0548 |
| March 31, 2021 | -0.6553 |
| December 31, 2020 | 0.2614 |
| September 30, 2020 | -11.86 |
| June 30, 2020 | -0.3352 |
| March 31, 2020 | -0.2271 |
| December 31, 2019 | -0.0912 |
| September 30, 2019 | -0.0536 |
| June 30, 2019 | -0.0298 |
| March 31, 2019 | -0.0465 |
| December 31, 2018 | -0.0759 |
| September 30, 2018 | -0.8978 |
| June 30, 2018 | -0.0079 |
| March 31, 2018 | -0.0192 |
| December 31, 2017 | 0.00 |
| September 30, 2017 | 0.00 |
| June 30, 2017 | 0.00 |
| March 31, 2017 | 0.00 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| NovelStem International Corp. | -0.0017 |
| Brainstorm Cell Therapeutics, Inc. | -0.3494 |
| Summit Therapeutics, Inc. | -0.2772 |
| Kezar Life Sciences, Inc. | -0.7838 |
| Protara Therapeutics, Inc. | -0.3552 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -13.42M |
| Revenue (Quarterly) | 0.09M |
| Total Expenses (Quarterly) | 13.51M |
| Enterprise Value | 64.81M |
| Gross Profit Margin (Quarterly) | -332.2% |
| Profit Margin (Quarterly) | -14.92K% |
| Earnings Yield | -86.09% |
| Normalized Earnings Yield | -62.12 |